Erratum to: NSAIDs Use and Reduced Metastasis in Cancer Patients: results from a meta-analysis (Scientific Reports, (2017), 7, 1, (1875), 10.1038/s41598-017-01644-0);NSAIDs use and reduced metastasis in cancer patients: Results from a meta-analysis

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Zhao, Xiaoping ^a   Xu, Zhi ^a   Li, Haoseng ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85019176527     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-28806-y     Document Type: Erratum

References (44)

1. Bibbins-Domingo, K., & Force, U. S. P. S. T. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 164, 836-845, doi:10.7326/M16-0577 (2016).
2. Huang, X. Z., et al. Aspirin and nonsteroidal anti-inflammatory drugs after but not before diagnosis are associated with improved breast cancer survival: a meta-Analysis. Cancer causes & control: CCC 26, 589-600, doi:10.1007/s10552-015-0539-y (2015).
3. Elwood, P. C., et al. Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies. PLoS One 11, e0152402, doi:10.1371/journal.pone.0152402 (2016).
4. Algra, A. M., & Rothwell, P. M. Effects of regular aspirin on long-Term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. The Lancet Oncology 13, 518-527, doi:10.1016/s1470-2045(12)70112-2 (2012).
5. Rothwell, P. M., et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. The Lancet 379, 1591-1601, doi:10.1016/s0140-6736(12)60209-8 (2012).
6. Holmes, M. D., et al. Aspirin intake and survival after breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 28, 1467-1472, doi:10.1200/JCO.2009.22.7918 (2010).
7. Choe, K. S., et al. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 30, 3540-3544, doi:10.1200/JCO.2011.41.0308 (2012).
8. Leitzmann, M. F., et al. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 11, 1108-1111 (2002).
9. Ljung, R., Sennerstam, R., Mattsson, F., Auer, G., & Lagergren, J. Anticoagulant medication at time of needle biopsy for breast cancer in relation to risk of lymph node metastasis. International journal of cancer 135, 238-241, doi:10.1002/ijc.28671 (2014).
10. Dell?Atti, L. Correlation between prolonged use of aspirin and prognostic risk in prostate cancer. Tumori 100, 486-490, doi:10.1700/1660.18156 (2014).
11. Jacobs, C. D., et al. Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy. Cancer biology & therapy 15, 699-706, doi:10.4161/cbt.28554 (2014).
12. Bradley, M. C., Black, A., Freedman, A. N., & Barron, T. I. Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: A cohort study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer 122, 2067-2075, doi:10.1002/cncr.30004 (2016).
13. Jonsson, F., et al. Low-dose aspirin use and cancer characteristics: a population-based cohort study. British journal of cancer 109, 1921-1925, doi:10.1038/bjc.2013.411 (2013).
14. Allott, E. H., et al. Non-steroidal anti-inflammatory drug use, hormone receptor status, and breast cancer-specific mortality in the Carolina Breast Cancer Study. Breast cancer research and treatment 147, 415-421, doi:10.1007/s10549-014-3099-z (2014).
15. Sharpe, C. R., et al. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. British journal of cancer 83, 112-120, doi:10.1054/bjoc.2000.1119 (2000).
16. Valsecchi, M. E., Pomerantz, S. C., Jaslow, R., & Tester, W. Reduced risk of bone metastasis for patients with breast cancer who use COX-2 inhibitors. Clinical breast cancer 9, 225-230, doi:10.3816/CBC.2009.n.038 (2009).
17. Araujo, J. L., et al. Prediagnosis aspirin use and outcomes in a prospective cohort of esophageal cancer patients. Therap Adv Gastroenterol 9, 806-814, doi:10.1177/1756283X16657985 (2016).
18. Barron, T. I., Flahavan, E. M., Sharp, L., Bennett, K., & Visvanathan, K. Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: a nationwide population-based cohort study. Cancer research 74, 4065-4077, doi:10.1158/0008-5472.CAN-13-2679 (2014).
19. Menezes, R. J., Swede, H., Niles, R., & Moysich, K. B. Regular use of aspirin and prostate cancer risk (United States). Cancer causes & control: CCC 17, 251-256, doi:10.1007/s10552-005-0450-z (2006).
20. Sansbury, L. B., et al. Use of nonsteroidal antIInflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites. American journal of epidemiology 162, 548-558, doi:10.1093/aje/kwi248 (2005).
21. Bowers, L. W., et al. NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-Aromatase interactions. Cancer research 74, 4446-4457, doi:10.1158/0008-5472.CAN-13-3603 (2014).
22. Forget, P., et al. Neutrophil:lymphocyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Annals of surgical oncology 20(Suppl 3), S650-660, doi:10.1245/s10434-013-3136-x (2013).
23. Rothwell, P. M., et al. Short-Term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379, 1602-1612, doi:10.1016/S0140-6736(11)61720-0 (2012).
24. Dhillon, P. K., Kenfield, S. A., Stampfer, M. J., & Giovannucci, E. L. Long-Term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. International journal of cancer 128, 2444-2452, doi:10.1002/ijc.25811 (2011).
25. Kwan, M. L., Habel, L. A., Slattery, M. L., & Caan, B. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer causes & control: CCC 18, 613-620, doi:10.1007/s10552-007-9003-y (2007).
26. Flossmann, E., & Rothwell, P. M. British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-Term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369, 1603-1613, doi:10.1016/S0140-6736(07)60747-8 (2007).
27. Smith, M. R., et al. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 24, 2723-2728, doi:10.1200/JCO.2005.03.7804 (2006).
28. Habel, L. A., Zhao, W., & Stanford, J. L. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer causes & control: CCC 13, 427-434 (2002).
29. Massague, J., & Obenauf, A. C. Metastatic colonization by circulating tumour cells. Nature 529, 298-306, doi:10.1038/nature17038 (2016).
30. Piskounova, E., et al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527, 186-191, doi:10.1038/nature15726 (2015).
31. Baandrup, L., Kjaer, S. K., Olsen, J. H., Dehlendorff, C., & FrIIs, S. Low-dose aspirin use and the risk of ovarian cancer in Denmark. Annals of oncology: official journal of the European Society for Medical Oncology 26, 787-792, doi:10.1093/annonc/mdu578 (2015).
32. Macfarlane, T. V., Murchie, P., & Watson, M. C. Aspirin and other non-steroidal anti-inflammatory drug prescriptions and survival after the diagnosis of head and neck and oesophageal cancer. Cancer epidemiology 39, 1015-1022, doi:10.1016/j.canep.2015.10.030 (2015).
33. McCowan, C., Munro, A. J., Donnan, P. T., & Steele, R. J. Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. European journal of cancer (Oxford, England: 1990) 49, 1049-1057, doi:10.1016/j.ejca.2012.10.024 (2013).
34. Algra, A. M., & Rothwell, P. M. Effects of regular aspirin on long-Term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13, 518-527, doi:10.1016/S1470-2045(12)70112-2 (2012).
35. Kinnunen, P. T., et al. Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer. Scandinavian journal of urology 50, 413-419, doi:10.1080/21681805.2016.1228085 (2016).
36. Rothwell, P. M., et al. Effect of daily aspirin on long-Term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet (London, England) 377, 31-41, doi:10.1016/s0140-6736(10)62110-1 (2011).
37. Liao, L. M., et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology 142, 442-452.e445; quiz e422-443, 10.1053/j.gastro.2011.11.019 (2012).
38. Salinas, C. A., et al. Use of aspirin and other nonsteroidal antIInflammatory medications in relation to prostate cancer risk. Am J Epidemiol 172, 578-590, doi:10.1093/aje/kwq175 (2010).
39. Chen, K., et al. Co-expression of CD133, CD44v6 and human tissue factor is associated with metastasis and poor prognosis in pancreatic carcinoma. Oncology reports 32, 755-763, doi:10.3892/or.2014.3245 (2014).
40. Wu, Y., & Zhou, B. P. Inflammation: a driving force speeds cancer metastasis. Cell cycle (Georgetown, Tex) 8, 3267-3273, doi:10.4161/cc.8.20.9699 (2009).
41. Hu, Y., Yu, X., Xu, G., & Liu, S. Metastasis: an early event in cancer progression. Journal of cancer research and clinical oncology 143, 745-757, doi:10.1007/s00432-016-2279-0 (2016).
42. Husemann, Y., et al. Systemic spread is an early step in breast cancer. Cancer cell 13, 58-68, doi:10.1016/j.ccr.2007.12.003 (2008).
43. Yuhara, H., et al. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? The American journal of gastroenterology 106, 1911-1921, quiz 1922, doi:10.1038/ajg.2011.301 (2011).
44. Zeng, W. T., Liu, Z. H., Li, Z. Y., Zhang, M., & Cheng, Y. J. Digoxin Use and Adverse Outcomes in Patients With Atrial Fibrillation. Medicine (Baltimore) 95, e2949, doi:10.1097/MD.0000000000002949 (2016).